Skip to content

Clinical study of rTMS in the treatment of vascular cognitive impairment

Clinical study of rTMS in the treatment of vascular cognitive impairment

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000039134
Enrollment
Unknown
Registered
2020-10-18
Start date
2020-07-01
Completion date
Unknown
Last updated
2021-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post stroke cognitive impairment

Interventions

NCI group:Nil
PSCIND group 1:Low frequency stimulation
PSCIND group 2:High frequency stimulation
PSCIND group 3:Sham stimulation
PSD group 1:Low frequency stimulation
PSD group 2:High frequency stimulation
PSD group 3:Sham stimulation
healthy control group:Nil

Sponsors

Xuzhou Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) The diagnosis meets the diagnostic criteria adopted by the Fourth National Cerebrovascular Disease Academic Conference of the Chinese Medical Association in 1995; (2) Aged 40-80 years, all underwent cranial CT and MRI examinations; (3) In line with the 2017 Chinese Stroke Society, Post-stroke Cognitive Impairment Management Expert Committee issued ["Expert Consensus on Post-stroke Cognitive Impairment Management" Post-stroke Cognitive Impairment(Post-stroke cognitive impairment, PSCI) diagnostic criteria; (4) Have sufficient visual and auditory resolution to accept neuropsychological tests; (5) The Hachinski Ischemia Scale (HIS) score of the post-stroke dementia group >=7; (6) Subjects and/or guardians give informed consent and sign the consent form.

Exclusion criteria

Exclusion criteria: (1) Exclude patients with a history of brain diseases other than cerebrovascular diseases, such as brain trauma, progressive supranuclear palsy, epilepsy, chronic subdural hematoma, Huntington's disease, normal pressure hydrocephalus,Brain infection, brain tumor or known abnormal brain structure, etc.; (2) Exclude patients with a history of neurodegenerative diseases, congenital, and genetic diseases. Exclude AD, Parkinson's disease, Lewy body dementia and other cerebrovascular factors caused by cognitionFunctional impairment; (3) Exclude patients with cognitive impairment caused by liver, kidney, thyroid and other system diseases or anemia, malnutrition and other reasons. Exclude consciousness disorders, severe neurological deficitsPatients with impairment, unable to take care of themselves, severe dementia, etc. who cannot complete the scale test; (4) Exclude patients who cannot complete the scale test due to hearing, vision, and language impairment, and have a history of alcohol, drug abuse or dependence within the past 2 years; (5) Exclude pseudo dementia caused by various other reasons; (6) Subjects whom the researcher believes cannot follow the research procedures; (7) Intracranial metal implants, magnetic sheets, pacemakers or skull defects; (8) Personal or family history of epilepsy and mental illness (including febrile convulsions in infancy); (9) Pregnancy.

Design outcomes

Primary

MeasureTime frame
Magnetic resonance spectroscopy;P300;Loewenstein Occupational Therapy Cognitive Assessment;mini-mental state examination, MMSE;Montreal cognitive assessment, MoCA;

Secondary

MeasureTime frame
Hachinski ischemic scale;

Countries

China

Contacts

Public ContactGong Zunke

Xuzhou Central Hospital

gongzunke@163.com+86 18952172330

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026